| Ytd | -7.69% | |
| 1y | 25.93% |
| Open | 2.07 | Prev Close | 2.05 | Low | 2.01 | High | 2.10 | Mkt Cap | 86.16M |
| Vol | 442.83K | Avg Vol | 544.26K | EPS | -1.30 | P/E | -1.57 | Forward P/E | -3.91 |
| Beta | 0.68 | Short Ratio | 3.62 | Inst. Own | 94.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 1.43 | 200-d Avg | 1.61 | 1yr Est | 11.92 |
LUNG News
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflecte
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consen
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx
REDWOOD CITY, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmon
REDWOOD CITY, Calif. , June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the "Co
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Re
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmon
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmon
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmon
Pulmonx Corporation (NASDAQ: LUNG - Get Free Report) has received an average recommendation of "Hold
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consen
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmon
